Clinical Trial Detail

NCT ID NCT02141828
Title A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Epizyme, Inc.
Indications

acute leukemia

acute lymphoblastic leukemia

acute myeloid leukemia

Therapies

Pinometostat

Age Groups: child

Additional content available in CKB BOOST